Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,373 shares of the pharmaceutical company’s stock after buying an additional 442 shares during the period. Sequoia Financial Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $6,399,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in VRTX. Total Clarity Wealth Management Inc. raised its position in Vertex Pharmaceuticals by 4.1% in the second quarter. Total Clarity Wealth Management Inc. now owns 1,262 shares of the pharmaceutical company’s stock valued at $562,000 after purchasing an additional 50 shares during the period. MGO One Seven LLC raised its holdings in Vertex Pharmaceuticals by 2.4% in the 2nd quarter. MGO One Seven LLC now owns 1,822 shares of the pharmaceutical company’s stock valued at $811,000 after buying an additional 43 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Vertex Pharmaceuticals by 16.6% in the second quarter. Allspring Global Investments Holdings LLC now owns 126,540 shares of the pharmaceutical company’s stock valued at $57,216,000 after buying an additional 18,011 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in shares of Vertex Pharmaceuticals by 7.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 38,491 shares of the pharmaceutical company’s stock valued at $17,138,000 after acquiring an additional 2,729 shares during the last quarter. Finally, Apollon Wealth Management LLC raised its stake in shares of Vertex Pharmaceuticals by 18.4% in the 2nd quarter. Apollon Wealth Management LLC now owns 29,757 shares of the pharmaceutical company’s stock valued at $13,248,000 after acquiring an additional 4,630 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.1%

VRTX stock opened at $407.37 on Tuesday. The company’s 50 day moving average is $392.61 and its two-hundred day moving average is $438.14. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.88. The stock has a market cap of $104.45 billion, a P/E ratio of 29.12 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. The firm had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the business posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analysts Set New Price Targets

VRTX has been the topic of several research analyst reports. Morgan Stanley cut their price objective on Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating on the stock in a report on Friday. Leerink Partnrs raised shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 25th. Stifel Nicolaus dropped their price objective on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating for the company in a report on Tuesday, August 5th. JPMorgan Chase & Co. increased their target price on shares of Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. Finally, HC Wainwright cut their price objective on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $494.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.